Optimisation of chemotherapy in the era of immunotherapy

René Boosman, Jacobus (Sjaak) Adrianus Burgers

Source: Eur Respir J, 52 (4) 1801698; 10.1183/13993003.01698-2018
Journal Issue: October
Disease area: Thoracic oncology

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
René Boosman, Jacobus (Sjaak) Adrianus Burgers. Optimisation of chemotherapy in the era of immunotherapy. Eur Respir J, 52 (4) 1801698; 10.1183/13993003.01698-2018

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.

Related content which might interest you:
Combination therapy in the era of immunotherapy
Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine
Year: 2019

Role of chemotherapy and radiation therapy
Source: Annual Congress 2012 - PG10 An update on mesothelioma diagnostics and treatment
Year: 2012

Concomitant radiotherapy and targeted therapies
Source: International Congress 2019 – New perspectives in thoracic surgical oncology
Year: 2019

Pitfalls of neoadjuvant treatment
Source: Annual Congress 2012 - Current challenges in multimodality lung cancer treatment
Year: 2012

Efficacy of induction chemotherapy and following simultaneous radiochemotherapy versus induction chemotherapy and radiotherapy alone in inoperable NSCLC (Stage IIIA/IIIB): update of CT/RT 99/97
Source: Annual Congress 2004 - Management of lung cancer and innovative therapies
Year: 2004

Surgery in the era of immune and targeted therapy
Source: Virtual Congress 2021 – Diagnostic and therapeutic advances in mesothelioma care
Year: 2021

Adjuvant therapy in NSCLC
Source: Annual Congress 2007 - Clinical year in review
Year: 2007

Systemic therapies: optimising the sequences of chemotherapies, targeted therapies and immunotherapies
Source: International Congress 2017 – PG1 Re-defining the role of chest physicians in lung cancer: new opportunities in diagnostics and therapy
Year: 2017

Neoadjuvant chemotherapy for NSCLC, lung function and surgical therapy – which is their connection?
Source: International Congress 2019 – Lung function testing: from experimental investigations to clinical applications
Year: 2019

Combination immunotherapy in mesothelioma: managing expectations and new toxicities
Source: Virtual Congress 2021 – Lung cancer grand round
Year: 2021

First-line therapy
Source: European Multidisciplinary Conference in Thoracic Oncology 2009
Year: 2009

Adjuvant and neoadjuvant therapy in nonsmall cell lung cancer (NSCLC)
Source: Annual Congress 2006 - Clinical year in review
Year: 2006